CRT Meeting

CRT Meeting CRT 2025 is an interventional cardiology meeting comprised of concurrent meetings in ten areas of interest. Visit CRTmeeting.org for more information.
(1)

CRT is a leading educational forum on new cardiovascular technology and procedures for physicians and health care professionals. Cardiovascular Research Technologies (CRT) is comprised of concurrent meetings in six main areas of interest— Valve & Structural Heart, Coronary, Endovascular, Technology and Innovation, and Nurses & Technologists. CRT provides a forum for exemplary education for interventional cardiologists as well as general cardiologists, cardiothoracic and vascular surgeons, cath lab managers, nurses and technologists, scientists and those with an interest in cardiovascular medicine. Join more than 3,000 interventional and endovascular specialists at CRT 2024 for a comprehensive four-day interventional cardiology conference in Washington, DC from March 9-12. For general inquiries, please email CRTmeeting@gmail.com.

A new review highlights that resistant hypertension occurs in 10% of patients with high blood pressure, and this kind of...
04/06/2026

A new review highlights that resistant hypertension occurs in 10% of patients with high blood pressure, and this kind of hypertension may be mitigated by lifestyle changes and pharmacotherapies. Read more on CRTonline.

A new review highlights that resistant hypertension occurs in 10% of patients with high blood pressure (BP), and this kind of hypertension may be mitigated by lifestyle changes and pharmacotherapies.

Noncalcified coronary plaque volume is not impacted by significant triglyceride and remnant cholesterol lowering for 12 ...
04/04/2026

Noncalcified coronary plaque volume is not impacted by significant triglyceride and remnant cholesterol lowering for 12 months with olezarsen therapy in addition to standard lipid lowering therapies, results from the ESSENCE-TIMI trial show. Read more from ACC 2026 on CRTonline.

Noncalcified coronary plaque volume is not impacted by significant triglyceride and remnant cholesterol lowering for 12 months with olezarsen therapy in addition to standard lipid lowering therapies,

Within 1-year after heart attack, outcomes are similar in patients who discontinue beta-blocker therapy versus patients ...
04/04/2026

Within 1-year after heart attack, outcomes are similar in patients who discontinue beta-blocker therapy versus patients who continue taking beta-blockers, demonstrating noninferiority in results from the SMART-DECISION trial. Read more from ACC 2026 on CRTonline.

Within 1-year after heart attack, outcomes are similar in patients who discontinue beta-blocker therapy versus patients who continue taking beta-blockers, demonstrating noninferiority in results from

T-TEER improves outcomes in patients with severe tricuspid regurgitation, such as cutting heart failure hospitalizations...
04/03/2026

T-TEER improves outcomes in patients with severe tricuspid regurgitation, such as cutting heart failure hospitalizations in half and reducing death rates, according to results from the TRI-FR trial. Read more from ACC 2026 on CRTonline.

Transcatheter tricuspid edge-to-edge repair (T-TEER) improves outcomes in patients with severe tricuspid regurgitation (TR), such as cutting heart failure (HF) hospitalizations in half and reducing de

Using the Emboliner system is safe and feasible in patients with severe aortic stenosis undergoing transcatheter aortic ...
04/03/2026

Using the Emboliner system is safe and feasible in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, according to results from the Protect The Head to Head study. Read more from ACC 2026 on CRTonline.

Using the Emboliner system is safe and feasible in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR), according to results from the Protect The Head to

Deferring percutaneous coronary intervention (PCI) in transcatheter aortic valve implantation (TAVI) significantly reduc...
04/02/2026

Deferring percutaneous coronary intervention (PCI) in transcatheter aortic valve implantation (TAVI) significantly reduces bleeding in patients with coronary artery disease (CAD) and is noninferior to the standard of PCI before TAVI, data from the PRO-TAVI trial show. Read more from ACC 2026 on CRTonline.

Deferring percutaneous coronary intervention (PCI) in transcatheter aortic valve implantation (TAVI) significantly reduces bleeding in patients with coronary artery disease (CAD) and is noninferior to

Mitral valve-in-valve (ViV) implantation is superior to redo-surgery in patients with failed mitral bioprosthesis, resul...
04/02/2026

Mitral valve-in-valve (ViV) implantation is superior to redo-surgery in patients with failed mitral bioprosthesis, results from the SURVIV trial show. Read more from ACC 2026 on CRTonline.

Mitral valve-in-valve (ViV) implantation is superior to redo-surgery in patients with failed mitral bioprosthesis, results from the SURVIV trial show.

04/02/2026

Welcome, Spring (Session) 🌼🌷🪻🪴🍄 CRT TV Spring Session takes place on Saturdays from April 11-May 2, 2026, you don't want to miss these exciting assemblies of experts discussing the latest and greatest in the field 🍄 Go to CRTTV.org to register today 🍄

Watch 🎥 Download 📥 Explore 🌏 with CRT Community Premium! Get your annual subscription today to take part in all CRTonlin...
04/01/2026

Watch 🎥 Download 📥 Explore 🌏 with CRT Community Premium! Get your annual subscription today to take part in all CRTonline has to offer, including meeting content, CardioTube videos and more 🫀

Data from the ORBITA-CTO trial demonstrate chronic total occlusion (CTO) percutaneous coronary intervention improves sym...
04/01/2026

Data from the ORBITA-CTO trial demonstrate chronic total occlusion (CTO) percutaneous coronary intervention improves symptoms in patients with single-vessel CTO and chronic chest pain. Read more from ACC 2026 on CRTonline.

Data from the ORBITA-CTO trial demonstrate chronic total occlusion (CTO) percutaneous coronary intervention (PCI) improves symptoms and quality-of-life in patients with single-vessel CTO and chronic c

Physiological assessment derived from angiographic images (FFRangio system) in patients with at least one intermediate c...
04/01/2026

Physiological assessment derived from angiographic images (FFRangio system) in patients with at least one intermediate coronary stenosis, who were considered for PCI, is noninferior to a pressure-wire-based strategy at 1-year in the ALL-RISE trial. Read more from ACC 2026 on CRTonline.

Physiological assessment derived from angiographic images (FFRangio system) in patients with at least one intermediate coronary stenosis, who were considered for percutaneous coronary intervention (PC

If it's Saturday, it's CRT TV Spring Session (say that five times fast) 🌱 the program is just as fun as the slogan. Revi...
03/31/2026

If it's Saturday, it's CRT TV Spring Session (say that five times fast) 🌱 the program is just as fun as the slogan. Review all the highlights from CRT 2026 and ACC 2026 on Saturdays this April and May with CRT TV! Go to CRTTV.org to register 🍃🦚

Address

Washington D.C., DC

Telephone

+12028777000

Website

Alerts

Be the first to know and let us send you an email when CRT Meeting posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CRT Meeting:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

CRT is a leading educational forum on new cardiovascular technology and procedures for physicians and health care professionals. Cardiovascular Research Technologies (CRT) is comprised of concurrent meetings in six main areas of interest— Valve & Structural Heart, Coronary, Endovascular, Technology and Innovation, and Nurses & Technologists. CRT provides a forum for exemplary education for interventional cardiologists as well as general cardiologists, cardiothoracic and vascular surgeons, cath lab managers, nurses and technologists, scientists and those with an interest in cardiovascular medicine. Join more than 2,000 interventional and endovascular specialists at CRT 2020 for a comprehensive four-day interventional cardiology conference in National Harbor, MD, from February 22-25, 2020. For general inquiries, please email CRTmeeting@gmail.com.